See more : Visa Inc. (V) Income Statement Analysis – Financial Results
Complete financial analysis of Aion Therapeutic Inc. (ANTCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aion Therapeutic Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- RWE Aktiengesellschaft (RWE.WA) Income Statement Analysis – Financial Results
- Sculptor Capital Management, Inc. (SCU) Income Statement Analysis – Financial Results
- Sparinvest Bæredygtige Aktier KL (SPIBDA.CO) Income Statement Analysis – Financial Results
- The First Bank Of Toyama, Ltd. (7184.T) Income Statement Analysis – Financial Results
- Melar Acquisition Corp. I Unit (MACIU) Income Statement Analysis – Financial Results
Aion Therapeutic Inc. (ANTCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Aion Therapeutic Inc.
Aion Therapeutic Inc. offer medical cannabis products in Canada. The company was formerly known as Osoyoos Cannabis Inc. and changed its name to Aion Therapeutic Inc. in August 2020. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 367.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 204.36K | 17.30K | 65.29K | 128.13K | 111.05K | 0.00 | 2.00K | 0.00 |
| Gross Profit | 163.12K | -17.30K | -65.29K | -128.13K | -111.05K | 0.00 | -2.00K | 0.00 |
| Gross Profit Ratio | 44.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 953.00K | 0.00 | 18.40K | 15.99K | 306.76K | 0.00 |
| General & Administrative | 967.81K | 738.50K | 1.13M | 2.17M | 579.12K | 1.02M | 127.50K | 51.27K |
| Selling & Marketing | 53.58K | 103.84K | 0.00 | 0.00 | 2.03K | 7.41K | 22.72K | 16.51K |
| SG&A | 1.02M | 842.33K | 1.13M | 2.17M | 579.12K | 1.03M | 150.22K | 67.78K |
| Other Expenses | -858.27K | 0.00 | 0.00 | 0.00 | 0.00 | -34.04K | 76.35K | 3.66K |
| Operating Expenses | 163.12K | 842.33K | 2.82M | 2.78M | 982.64K | 1.70M | 207.43K | 125.58K |
| Cost & Expenses | 367.48K | 842.33K | 2.82M | 2.78M | 982.64K | 1.70M | 207.43K | 125.58K |
| Interest Income | 14.99K | 149.84 | 75.72 | 186.07 | 321.19 | 679.12 | 0.00 | 0.00 |
| Interest Expense | 171.39K | 149.84K | 75.72K | 186.07K | 321.19K | 679.12K | 9.04K | 11.37K |
| Depreciation & Amortization | 42.11K | 17.30K | 65.29K | 128.13K | 111.05K | 1.49M | 2.53M | 52.52K |
| EBITDA | -6.07M | -842.33K | -2.33M | -2.47M | -851.62K | 0.00 | 0.00 | -121.92K |
| EBITDA Ratio | -1,652.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | -842.33K | -2.82M | -2.78M | -996.64K | -1.70M | -131.08K | -121.92K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.29M | 585.68K | -1.49M | -5.79M | 178.79K | -3.44M | -314.21K | -1.38M |
| Income Before Tax | -6.29M | -256.66K | -3.82M | -8.27M | -672.83K | -4.93M | -140.11K | -1.51M |
| Income Before Tax Ratio | -1,710.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 41.03K | 75.72K | 186.07K | 321.19K | 677.63K | -2.44M | -37.49K |
| Net Income | -6.29M | -256.66K | -3.82M | -8.27M | -672.83K | -4.93M | -140.11K | -1.51M |
| Net Income Ratio | -1,710.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | -0.03 | -0.09 | -0.02 | -0.18 | 0.00 | -0.04 |
| EPS Diluted | 0.00 | 0.00 | -0.03 | -0.09 | -0.02 | -0.18 | 0.00 | -0.04 |
| Weighted Avg Shares Out | 0.00 | 146.40M | 139.89M | 93.90M | 35.89M | 27.48M | 34.67M | 34.67M |
| Weighted Avg Shares Out (Dil) | 0.00 | 146.40M | 139.89M | 93.90M | 35.89M | 27.48M | 34.67M | 34.67M |
3 Weed Stocks to Buy Before Marijuana Goes Mainstream (i.e., Circle K, Uber Eats)
Two things recently happened that have investors thinking more seriously about weed stocks to buy. First, Uber Eats (NYSE: UBER ) and cannabis information platform operator Leafly (NASDAQ: LFLY ) announced they had begun partnering on cannabis delivery in Toronto,...
Aion Therapeutic Inc announces intellectual property sale to Apollon Formularies
AION Therapeutic Inc. (CSE:AION) said it has sold four patent applications and all associated supporting data to Apollon Formularies PLC (AQSE:APOL), a UK-based international pharmaceutical company listed on the Aquis Stock Exchange. In consideration for the intellectual property, Apollon has...
Aion Therapeutic looks ready to prove that cannabis and ‘magic' mushrooms are a good therapeutic mix
Recently acquired a Jamaica-based pharmaceutical company Unique research that combines medical cannabis with psychedelic mushrooms Artificial-Intelligence (AI) driven development of combinatorial pharmaceuticals What Aion Therapeutic does: Toronto-based Aion Therapeutic Inc (CSE:AION), formerly Osoyoos Cannabis Inc, intends to process raw cannabis...
Aion Therapeutic Combines the Healing Powers of Cannabinoids and Psychedelics to Treat Cancer and Depression
To date, 74% of prescription drugs are derived from plants, 18% specifically from fungi. Still, many companies hesitate to invest in the medicinal benefits of mushrooms.
Source: https://incomestatements.info
Category: Stock Reports